These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25619634)

  • 1. Improving adherence to and persistence with oral therapy of osteoporosis.
    Bianchi ML; Duca P; Vai S; Guglielmi G; Viti R; Battista C; Scillitani A; Muscarella S; Luisetto G; Camozzi V; Nuti R; Caffarelli C; Gonnelli S; Albanese C; De Tullio V; Isaia G; D'Amelio P; Broggi F; Croci M
    Osteoporos Int; 2015 May; 26(5):1629-38. PubMed ID: 25619634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
    Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
    Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.
    van Maren MA; Wyers CE; Driessen JHM; Visser JV; de Vries F; van de Wijdeven K; Gevers S; Lems WF; Emmelot-Vonk MH; van den Bergh JPW
    Osteoporos Int; 2019 Sep; 30(9):1837-1844. PubMed ID: 31321446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
    Akarırmak Ü; Koçyiğit H; Eskiyurt N; Esmaeilzadeh S; Kuru Ö; Yalçinkaya EY; Peker Ö; Ekim AA; Özgirgin N; Çalış M; Rezvani A; Çevikol A; Eyigör S; Şendur ÖF; İrdesel J;
    Acta Orthop Traumatol Turc; 2016 Aug; 50(4):415-23. PubMed ID: 27524671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study.
    Clark EM; Gould VC; Tobias JH; Horne R
    Osteoporos Int; 2016 Feb; 27(2):579-90. PubMed ID: 26286625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial.
    Silverman SL; Nasser K; Nattrass S; Drinkwater B
    Osteoporos Int; 2012 Mar; 23(3):1069-74. PubMed ID: 21755401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
    Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
    Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
    J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
    Vytrisalova M; Touskova T; Ladova K; Fuksa L; Palicka V; Matoulkova P; Horak P; Stepan J
    Climacteric; 2015; 18(4):608-16. PubMed ID: 25495333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and persistence in patients with severe osteoporosis treated with teriparatide.
    Ziller V; Zimmermann SP; Kalder M; Ziller M; Seker-Pektas B; Hellmeyer L; Hadji P
    Curr Med Res Opin; 2010 Mar; 26(3):675-81. PubMed ID: 20078188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.
    Karlsson L; Lundkvist J; Psachoulia E; Intorcia M; Ström O
    Osteoporos Int; 2015 Oct; 26(10):2401-11. PubMed ID: 26282229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
    Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
    Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study.
    Guilera M; Fuentes M; Grifols M; Ferrer J; Badia X;
    Osteoporos Int; 2006; 17(5):664-71. PubMed ID: 16437191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial.
    Solomon DH; Gleeson T; Iversen M; Avorn J; Brookhart MA; Lii J; Losina E; May F; Patrick A; Shrank WH; Katz JN
    Osteoporos Int; 2010 Jan; 21(1):137-44. PubMed ID: 19436935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial.
    Cizmic AD; Heilmann RM; Milchak JL; Riggs CS; Billups SJ
    Osteoporos Int; 2015 Aug; 26(8):2131-6. PubMed ID: 25956282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database.
    Confavreux CB; Canoui-Poitrine F; Schott AM; Ambrosi V; Tainturier V; Chapurlat RD
    Eur J Endocrinol; 2012 Apr; 166(4):735-41. PubMed ID: 22258112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday.
    Eliasaf A; Amitai A; Maram Edry M; Yosselson Superstine S; Rotman Pikielny P
    J Clin Pharmacol; 2016 Nov; 56(11):1416-1422. PubMed ID: 26999526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.